Core Insights - Bristol Myers Squibb and SystImmune have reported data from an early-stage study on their bispecific antibody-drug conjugate, iza-bren, targeting advanced non-small cell lung cancer and other solid tumors [2] Company Overview - Iza-bren is a collaborative development between SystImmune and Bristol Myers Squibb [2]